JPH0522687B2 - - Google Patents
Info
- Publication number
- JPH0522687B2 JPH0522687B2 JP12340684A JP12340684A JPH0522687B2 JP H0522687 B2 JPH0522687 B2 JP H0522687B2 JP 12340684 A JP12340684 A JP 12340684A JP 12340684 A JP12340684 A JP 12340684A JP H0522687 B2 JPH0522687 B2 JP H0522687B2
- Authority
- JP
- Japan
- Prior art keywords
- active oxygen
- fuisetin
- pma
- effects
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical class N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12340684A JPS615016A (ja) | 1984-06-15 | 1984-06-15 | 活性酸素除去剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12340684A JPS615016A (ja) | 1984-06-15 | 1984-06-15 | 活性酸素除去剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS615016A JPS615016A (ja) | 1986-01-10 |
| JPH0522687B2 true JPH0522687B2 (enrdf_load_stackoverflow) | 1993-03-30 |
Family
ID=14859764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12340684A Granted JPS615016A (ja) | 1984-06-15 | 1984-06-15 | 活性酸素除去剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS615016A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0712529U (ja) * | 1993-08-09 | 1995-03-03 | 鹿島建設株式会社 | 地下連続壁掘削機の掘削アタッチメント洗浄装置 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
| DE10359384A1 (de) * | 2003-12-18 | 2005-07-28 | Anoxymer Gmbh | Verwendung eines Extraktes von Aloysia triphylla als Matrixprotektor |
| KR102139659B1 (ko) * | 2015-12-08 | 2020-07-30 | 주식회사 엘지생활건강 | 피부 개선용 조성물 |
-
1984
- 1984-06-15 JP JP12340684A patent/JPS615016A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0712529U (ja) * | 1993-08-09 | 1995-03-03 | 鹿島建設株式会社 | 地下連続壁掘削機の掘削アタッチメント洗浄装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS615016A (ja) | 1986-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100638684B1 (ko) | 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도 | |
| Mahmoud et al. | Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma | |
| Billah et al. | Pharmacology of N-(3, 5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor | |
| JPWO2002055088A1 (ja) | 骨髄抑制治療剤、感染症治療剤及び白血球数増加剤 | |
| WO2003086074A1 (en) | Method for treating hepatic encephalopathies | |
| CA2136977A1 (en) | _-8-tetrahydro-cannabinol as antiemetic | |
| US6498173B1 (en) | Synergistic combination comprising roflumilast and a pde-3 inhibitor | |
| JPH0352815A (ja) | 血管内血液凝固症候群の治療剤 | |
| JPH0522687B2 (enrdf_load_stackoverflow) | ||
| JP2006515361A (ja) | ヘルペスウイルス感染の症候を治療又は予防する方法 | |
| JPH06500537A (ja) | アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用 | |
| US5153221A (en) | Method for the treatment of acquired immune deficiency syndrome | |
| JPH02184632A (ja) | 医薬組成物 | |
| JP2002308764A (ja) | 眼科用医薬組成物 | |
| EP0256629A2 (en) | Tolrestat or a salt thereof as an immuno-stimulating agent | |
| EP0347927A2 (de) | Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on (Ebselen) zur Herstellung von Arzneimitteln zur Behandlung von Malaria | |
| US3423508A (en) | Method of combatting herpes virus with 5-nitrouracil | |
| Chou | Advances in antiviral therapy | |
| JP2816499B2 (ja) | 糖尿病治療剤 | |
| JPS6111A (ja) | 脱髄性疾患治療剤 | |
| JPH07165588A (ja) | 脳機能改善剤 | |
| JPH0296521A (ja) | 免疫性疾患治療剤 | |
| US4731380A (en) | Tolerstat as an agent for diabetic periodontitis | |
| JPS62267227A (ja) | 血中尿酸濃度の低下用医薬 | |
| JPS6330421A (ja) | 口腔部局所投与剤 |